Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

72.16EUR
11:35am EDT
Change (% chg)

€-0.69 (-0.95%)
Prev Close
€72.85
Open
€72.85
Day's High
€73.45
Day's Low
€71.85
Volume
2,979,923
Avg. Vol
2,669,101
52-wk High
€86.39
52-wk Low
€62.88

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €91,975.98
Shares Outstanding(Mil.): 1,251.54
Dividend: 3.03
Yield (%): 4.16

Financials

  SASY.PA Industry Sector
P/E (TTM): 28.32 28.54 30.58
EPS (TTM): 2.57 -- --
ROI: 3.63 13.15 12.84
ROE: 5.70 15.15 15.02

Amicus Therapeutics receives U.S. approval for Fabry disease drug

U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Aug 10 2018

German stocks - Factors to watch on August 9

FRANKFURT/BERLIN, Aug 9 The following are some of the factors that may move German stocks on Thursday:

Aug 09 2018

More drugmakers build Brexit stockpiles as EU agency faces exodus

PARIS/ZURICH/LONDON Sanofi and Novartis said on Wednesday they planned to increase stockpiles of medicines in Britain in preparation for potential disruption if the UK crashes out of the European Union without a deal. | Video

Aug 01 2018

Sanofi has been stockpiling drugs for no-deal Brexit - WSJ

French drugmaker Sanofi has been making drug-shortage contingency plans for more than a year to prepare for Britain and the European Union failing to reach a Brexit transition deal, the Wall Street Journal reported on Tuesday, citing a source. | Video

Aug 01 2018

More drugmakers build Brexit stockpiles as EU agency faces exodus

PARIS/ZURICH/LONDON Sanofi and Novartis said on Wednesday they planned to increase stockpiles of medicines in Britain in preparation for potential disruption if the UK crashes out of the European Union without a deal.

Aug 01 2018

Sanofi stockpiling in UK in case of Brexit no-deal - statement

PARIS, Aug 1 Sanofi on Wednesday said it had made arrangements for additional warehouse capacity in Britain to stockpile products, as it makes contingency plans for a no-deal in Brexit negotiations.

Aug 01 2018

Sanofi has been stockpiling drugs for no-deal Brexit: WSJ

French drugmaker Sanofi has been making drug-shortage contingency plans for more than a year to prepare for Britain and the European Union failing to reach a Brexit transition deal, the Wall Street Journal reported on Tuesday, citing a source.

Jul 31 2018

Sanofi has been stockpiling drugs for no-deal Brexit - WSJ

July 31 French drugmaker Sanofi has been making drug-shortage contingency plans for more than a year to prepare for Britain and the European Union failing to reach a Brexit transition deal, the Wall Street Journal reported on Tuesday, citing a source.

Jul 31 2018

Genzyme rare disease drug sales drive Sanofi profit

PARIS Strong sales growth at Sanofi's Genzyme rare diseases business drove better than expected second quarter profit, allowing the French drugmaker to narrow its 2018 target.

Jul 31 2018

UPDATE 3-Genzyme rare disease drug sales drive Sanofi profit

* 2018 EPS growth now expected between 3 and 5 percent (Adds Dupixent figures, shares, comment)

Jul 31 2018

Earnings vs. Estimates